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OBJECTIVES: To evaluate the impact of golimumab (GLM)
on productivity in ankylosing spondylitis (AS) patients.
METHODS: GLM was studied in a multicenter, randomized,
placebo (PBO)-controlled study (GO-RAISE). A total of 356
patients were randomized (1.8:1.8:1 ratio) to receive subcutane-
ous GLM 50 mg or 100 mg or PBO q4wks. Patients with AS
according to the modiﬁed NY criteria (BASDAI and back pain
score each 34) were eligible. Productivity was measured on a VAS
scale (0–10 cm). Change in productivity from baseline to wk16
and wk24 was compared between groups. At wk16, patients in
the PBO or GLM 50 mg group who had <20% improvement in
total back pain and morning stiffness measures entered early
escape in a double-blind fashion. All other patients remained on
their previous medication until wk24. For GLM 50 mg or PBO
patients who entered early escape, their last observation prior to
change in treatment was carried forward for the wk24 analyses.
Observed values at wk24 were used for GLM 100 mg patients.
An ANOVA on van der Waerden normal scores was performed
for between-group differences. RESULTS: Patients in the GLM
50 mg, 100 mg, and PBO groups had similar mean  SD base-
line scores of 6.6  2.5, 6.8  2.3 and 6.3  2.5, respectively.
Mean improvement in self-reported productivity was signiﬁ-
cantly greater in the GLM 50 mg group vs. PBO at wk16
(-2.8  3.0 vs. -0.4  2.7; p < 0.001) and wk24 (-2.7  3.1 vs.
-0.5  3.0; p < 0.001), and was also signiﬁcantly greater in the
GLM 100 mg group vs. PBO at wk16 (-2.9  2.9 vs -0.4  2.7;
p < 0.001) and wk24 (-2.9  3.0 vs. -0.5  3.0; p < 0.001). The
change from baseline in productivity was similar in the GLM
50 mg and GLM 100 mg groups at wk16 and wk24. CONCLU-
SIONS: A patients treated with GLM 50 mg and 100 mg had
signiﬁcant improvement in self-reported productivity, with
improvement at wk16 maintained through wk24.
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OBJECTIVES: To develop an electronic version of the Health
Assessment Questionnaire Disability Index (HAQ-DI) for use on
a handheld computer and to assess the equivalence of the elec-
tronic and paper versions in patients with rheumatoid arthritis.
METHODS: Development of the electronic version involved sig-
niﬁcant modiﬁcation, in particular eliminating free text entry.
The conceptual framework of the scale was not altered, and the
electronic version was aligned to the original scoring scheme.
Equivalence of scores was evaluated in a crossover study in
which patients completed a series of questionnaires including the
HAQ-DI once in electronic and once in paper mode in ran-
domised order with a 45-minute interval in between. Patients
then completed a questionnaire on ease of use and acceptability
of the two modes. Agreement was assessed using intraclass cor-
relation coefﬁcients (ICC), mean differences between electronic
and paper scores, and Bland-Altman plots. RESULTS: Forty-
three patients, 12 male and 31 female, aged 32–83 years, com-
pleted the study. Overall agreements between the paper and
electronic questionnaires was excellent (HAQ-DI: ICC = 0.963).
Comparison of mean differences showed no evidence for bias in
electronic vs. paper scores. The mean difference between elec-
tronic and paper scores was 0.03 units (S.D. 0.20), correspond-
ing to 1% of the total scale length. Most patients found both
paper and electronic questionnaires easy to use, and all patients
found both modes acceptable. Six patients preferred paper, 23
preferred electronic, and 14 expressed no preference. CONCLU-
SIONS: There was excellent agreement between electronic and
paper administration of the HAQ, suggesting that migration
from paper to electronic had not led to any signiﬁcant change in
the data collected. Electronic methods of data collection were
well-liked by patients and highly acceptable. The results support
the use of the electronic version of this scale in clinical studies in
rheumatoid arthritis.
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OBJECTIVES: To develop and validate a brief generic question-
naire to assess patients’ satisfaction with pharmacological treat-
ment in chronic diseases. METHODS: An extensive literature
review was conducted to create an initial item pool of 41 ques-
tions regarding, exclusively, satisfaction with medication. Next,
two physicians and two English-Spanish translators carried out
item forward-backward translation into Spanish. Moreover,
comprehension and importance of items (C/I) were assessed by
experts’ (5 physicians, 2 nurses and 1 psychologist) and patients’
(n = 30) panels leading to an initial version of 20 items. Finally,
scale item reduction and validation (feasibility, reliability and
validity properties) of the ﬁnal SAT-Q were carried with patients
from 4 Primary Health Centres. RESULTS: In total 202 patients
(65.35% female) were collected and 196 patients (97.5%) com-
pleted the questionnaire correctly. Exploratory factorial analysis
(FA) and item-total correlation lead to a reduced ﬁnal question-
naire (13 items). Conﬁrmatory FA (oblimin rotation) revealed 1
general domain, global satisfaction (3 items, 72.35% of variance
explained, Cronbach’s a: 0.81) along with 4 speciﬁc domains
(eigenvalues >1.0): side-effects (3 items, 32.49% of variance
explained, Cronbach’s a: 0.76) oversights (2 items, 14.85%,
Cronbach’s a: 0.71), treatment effectiveness (3 items, 13.92%,
Cronbach’s a: 0.74), adherence (2 items, 10.23%, Cronbach’s a:
0.53). Overall, test-retest correlations (n = 50) were signiﬁcative
(p < 0.001): global satisfaction (0.69), treatment effectiveness
(0.63); side-effects (0.46), adherence (0.64) oversights (0.88).
Correlations between domains and Physical and Mental
Summary Components of SF-12 Health Survey were respectively:
global satisfaction (0.39 and 0.30; p < 0.001), treatment effec-
tiveness (0.33 and 0.19 p < 0.001); side-effects (0.35 and 0.35;
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